In this report, the Global Blood Screening Market has been segmented by Technology, Product, End Use, and Geography.

Global Blood Screening Market, Segmentation by Technology

The Global Blood Screening Market has been segmented by Technology into Nucleic Acid Amplification Test (NAT), Enzyme-linked Immunosorbent Assay (ELISA), Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA), Next-Generation Sequencing (NGS) and Western Blotting.

Nucleic Acid Amplification Test (NAT)

The Nucleic Acid Amplification Test (NAT) is a highly sensitive method used in blood screening to detect low levels of viral genetic material. It plays a critical role in identifying infections like HIV and Hepatitis B/C during the early window period. With a growing preference in blood banks and hospitals, NAT currently holds a market share of over 38%, reflecting its widespread adoption and accuracy.

Enzyme-linked Immunosorbent Assay (ELISA)

ELISA remains one of the most established technologies in blood screening, especially valued for its reliability and cost-effectiveness in detecting antibodies and antigens. Commonly used in blood banks globally, ELISA contributes to approximately 27% of the market, thanks to its robust performance and widespread accessibility in both developed and developing regions.

Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA)

CLIA and EIA offer enhanced sensitivity and faster processing times compared to traditional methods. CLIA, in particular, has gained traction due to its automation compatibility and high-throughput capabilities. These technologies together command around 18% of the market, with increasing applications in high-volume clinical laboratories.

Next-Generation Sequencing (NGS)

Next-Generation Sequencing (NGS) is an emerging blood screening technique known for its comprehensive analysis of pathogens. Though still in a nascent stage with a market share of roughly 10%, NGS is gaining attention for its potential in precision diagnostics and personalized medicine, particularly in specialized research settings.

Western Blotting

Western Blotting is traditionally used as a confirmatory test for infections such as HIV. Despite being less favored for large-scale screening due to its labor-intensive process, it still maintains a niche presence in the market. Currently, it holds a market share of around 7%, mainly used for secondary validation in diagnostic workflows.

Global Blood Screening Market, Segmentation by Product

The Global Blood Screening Market has been segmented by Product into Reagent and Instrument.

Reagent

Reagents dominate the global blood screening market, accounting for approximately 68% of the total share. These essential components are used in a wide array of testing technologies to detect infections with high precision. The growing demand for reliable and high-quality screening reagents in both developed and emerging markets is driving consistent growth in this segment.

Instrument

Instruments used in blood screening, such as analyzers and automated systems, represent about 32% of the market. The push for advanced, high-throughput screening equipment is rising, especially in centralized labs and hospitals aiming for faster diagnostics. Innovations in automated platforms are further enhancing operational efficiency and accuracy in blood testing procedures.

Global Blood Screening Market, Segmentation by End Use

The Global Blood Screening Market has been segmented by End Use into Blood Banks, Hospitals.

Blood Banks

Blood banks are the leading end users in the blood screening market, contributing to around 61% of the global share. Their role in maintaining safe and infection-free blood supplies makes rigorous screening protocols essential. With increasing blood donation drives and demand for transfusion safety, the need for advanced screening technologies in blood banks is on the rise.

Hospitals

Hospitals account for approximately 39% of the market, driven by the growing need for on-site screening before surgeries and medical treatments. The adoption of automated screening systems in hospital settings ensures quick turnaround and supports clinical efficiency. As patient volume increases, so does the demand for reliable blood testing infrastructure.

Global Blood Screening Market, Segmentation by Geography

In this report, the Global Blood Screening Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.

Global Blood Screening Market Share (%), by Geographical Region, 2024

North America

North America holds the largest share in the global blood screening market, accounting for approximately 42%. This dominance is attributed to its well-established healthcare infrastructure, high awareness levels, and the presence of leading diagnostic companies. The widespread adoption of advanced screening technologies further fuels regional growth.

Europe

Europe follows closely with around 26% of the global market. Strong government regulations on blood safety, coupled with increasing public health initiatives, drive the adoption of screening solutions across the region. Countries like Germany, France, and the UK are major contributors to this growth.

Asia Pacific

The Asia Pacific region is emerging rapidly, contributing to approximately 19% of the market. Rising demand for safe blood transfusions, a growing population, and increased healthcare spending are driving market expansion. Countries such as China, India, and Japan are investing in modern screening technologies to improve diagnostic accuracy.

Middle East and Africa

The Middle East and Africa represent about 8% of the global blood screening market. Although still developing, the region is witnessing improvements in healthcare access and infection control measures. Increased efforts to combat blood-borne diseases are boosting the adoption of screening practices.

Latin America

Latin America accounts for nearly 5% of the global share. Growth in this region is fueled by expanding healthcare infrastructure, government-led awareness programs, and efforts to enhance blood safety. Countries like Brazil and Mexico are leading the regional adoption of modern screening solutions.

This report provides an in depth analysis of various factors that impact the dynamics of Global Blood Screening Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.

Drivers, Restraints and Opportunities Analysis

Drivers

• Increasing Demand for Blood Transfusions
• Stringent Regulatory Standards
• Growing Awareness of Blood Safety

• Rising Incidence of Infectious Diseases - The global blood screening market is experiencing strong growth due to the increasing prevalence of infectious diseases around the world. Rising cases of illnesses such as HIV, hepatitis, and other blood-borne infections have intensified the need for effective blood screening solutions that ensure safe transfusions and reduce transmission risks. Healthcare systems are now focusing heavily on adopting advanced screening technologies to meet these growing safety demands.

  Improvements in screening accuracy and speed have made it possible to identify infections earlier, which is critical for patient care and containment efforts, especially in regions with a high burden of infectious diseases. This has led to increased deployment of cutting-edge blood testing methods across hospitals and blood banks.

  Strict government regulations and enhanced awareness among healthcare providers and patients are also driving the market. Blood screening is becoming a mandatory standard in many countries, pushing healthcare facilities to invest in the latest screening equipment.As infectious disease cases continue to rise globally, the emphasis on robust and reliable blood screening protocols will remain a major factor propelling market expansion and technological innovation.

Restraints

• High testing equipment costs
• Regulatory compliance complexities
• Limited access in low-income areas

• Sample contamination risks - One of the significant challenges restraining the global blood screening market is the risk of sample contamination, which can compromise test accuracy. Contaminated samples may lead to false positive or false negative results, negatively affecting blood safety and patient outcomes. Preventing contamination requires strict adherence to quality control measures and highly trained laboratory personnel.

  The complexity of maintaining contamination-free environments across multiple healthcare settings, especially in low-resource areas, poses a persistent obstacle. Inconsistent sample handling procedures and limited infrastructure further increase the risk of errors, undermining trust in blood screening results.

  False results due to contamination can cause unnecessary disposal of viable blood units or missed infections, creating inefficiencies and higher operational costs. Addressing these issues demands continuous investment in standardized protocols, staff training, and reliable equipment maintenance to enhance the overall quality of blood screening.Overcoming contamination risks is essential for ensuring the widespread adoption of advanced blood screening technologies and maintaining the safety and reliability of blood supplies worldwide.

Opportunities

• Development of rapid screening kits
• Expansion in emerging healthcare markets
• Integration with digital health records

• Point-of-care testing growth - The expansion of point-of-care testing (POCT) represents a promising opportunity in the global blood screening market. POCT devices offer rapid, onsite testing capabilities that allow healthcare providers to obtain critical blood screening results quickly, improving patient management, especially in emergencies and remote locations where access to centralized labs is limited.

  The convenience and efficiency of POCT systems have increased their adoption, as they help reduce the turnaround time for blood analysis, enabling faster clinical decisions and enhancing patient care outcomes. These portable and easy-to-use devices also reduce logistical challenges related to sample transport.

  Recent advancements have improved the sensitivity and specificity of POCT devices, making their results more comparable to traditional laboratory tests. Integration with digital health platforms allows seamless data management and remote monitoring, further enhancing healthcare delivery. As healthcare systems worldwide aim to decentralize diagnostic services and improve accessibility, investment in point-of-care blood screening technologies is expected to accelerate, presenting significant growth prospects for market participants.

Key players in Global Blood Screening Market include:

• Abbott Laboratories
• Bio-Rad Laboratories, Inc
• Grifols, S.A
• F. Hoffmann-La Roche Ltd
• Siemens Healthineers AG
• Thermo Fisher Scientific Inc
• Ortho Clinical Diagnostics
• Danaher Corporation
• Becton, Dickinson and Company (BD)
• Beckman Coulter, Inc

In this report, the profile of each market player provides following information:

• Company Overview and Product Portfolio
• Market Share Analysis
• Key Developments
• Financial Overview
• Strategies
• Company SWOT Analysis